Dostinex, for hyperprolactinemia, and launched Estring
in the United
Estring is a soft, flexible ring for insertion into the vagina that releases a low, continuous dose of estradiol (an estrogen produced by the ovaries) for 90 days.
In clinical trials with Estring, a majority of women who had previously used another hormonal product prior to Estring stated a preference for the Estring Vaginal Ring.
Estring is a slightly opaque, soft and flexible elastomer ring with an outer diameter of about two inches (55 mm) and a cross-sectional diameter of about 3/8 inch (9 mm).
First approved in Sweden in 1993, Estring is currently available in many countries, including the United Kingdom, Canada, New Zealand, South Africa and Switzerland.
Parkinson's Disease in Europe and Estring for Postmenopausal
In addition to Estring (estradiol vaginal ring) for Postmenopausal Urogenital Symptoms, further launches expected during 1996 include Xalatan (latanoprost) for the treatment of glaucoma, Sogilen (cabergoline) for Parkinson's disease and, possibly, Camptosar for colorectal cancer.
NYSE: PNU) announced today that it has received clearance to market Estring (estradiol vaginal ring) in the United States.
Estring is the only product that treats both vaginal and urogenital symptoms of UGA.
A prescription product, Estring is an elastomer ring containing 2 mg of 17 beta-estradiol, the major naturally occurring estrogen produced in the ovaries of fertile women.
Upjohn and Pharmacia have also entered into a separate five-year exclusive co-promotion agreement to market Pharmacia's Fragmin (anti- thrombosis), Mycobutin (infectious disease) and Estring (post-menopause) products in the U.
Pharmacia & Upjohn expects to launch Pharmacia's Fragmin (anti-thrombosis), Latanoprost (glaucoma), Estring (post-menopause) and Genotropin (growth hormone deficiency), in addition to Upjohn's Caverject (erectile dysfunction) and Freedox (sub-arachnoid hemorrhage) after regulatory approvals.